Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
The closing price of Wave Life Sciences Ltd (NASDAQ: WVE) was $9.51 for the day, down -2.36% from the previous closing price of $9.74. In other words, the price has decreased by -$2.36 from its previous closing price. On the day, 1.69 million shares were traded. WVE stock price reached its highest trading level at $9.785 during the session, while it also had its lowest trading level at $9.26.
Ratios:
Our analysis of WVE’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 2.56 and its Current Ratio is at 2.56. In the meantime, Its Debt-to-Equity ratio is 0.15 whereas as Long-Term Debt/Eq ratio is at 0.09.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Canaccord Genuity on August 04, 2025, initiated with a Buy rating and assigned the stock a target price of $19.
On July 28, 2025, Oppenheimer started tracking the stock assigning a Outperform rating and target price of $24.
On July 16, 2025, Citigroup started tracking the stock assigning a Buy rating and target price of $16.Citigroup initiated its Buy rating on July 16, 2025, with a $16 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Aug 15 ’25 when Tan Aik Na sold 21,000 shares for $9.25 per share. The transaction valued at 194,250 led to the insider holds 40,388 shares of the business.
AIK NA TAN bought 21,000 shares of WVE for $194,250 on Aug 15 ’25. On Aug 13 ’25, another insider, HENRY CHRISTIAN O, who serves as the Director of the company, sold 9,670 shares for $8.81 each. As a result, the insider received 85,193 and left with 29,645 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, WVE now has a Market Capitalization of 1514248832 and an Enterprise Value of 1371132032. For the stock, the TTM Price-to-Sale (P/S) ratio is 16.11 while its Price-to-Book (P/B) ratio in mrq is 10.63. Its current Enterprise Value per Revenue stands at 14.595 whereas that against EBITDA is -9.8.
Stock Price History:
The Beta on a monthly basis for WVE is -1.16, which has changed by 0.625641 over the last 52 weeks, in comparison to a change of 0.14064062 over the same period for the S&P500. Over the past 52 weeks, WVE has reached a high of $16.74, while it has fallen to a 52-week low of $5.04. The 50-Day Moving Average of the stock is 22.30%, while the 200-Day Moving Average is calculated to be -3.16%.
Shares Statistics:
WVE traded an average of 1.40M shares per day over the past three months and 1773890 shares per day over the past ten days. A total of 155.67M shares are outstanding, with a floating share count of 126.80M. Insiders hold about 20.32% of the company’s shares, while institutions hold 83.51% stake in the company. Shares short for WVE as of 1753920000 were 16079323 with a Short Ratio of 11.52, compared to 1751241600 on 15801693. Therefore, it implies a Short% of Shares Outstanding of 16079323 and a Short% of Float of 13.669999999999998.
Earnings Estimates
Currently, 11.0 analysts are dedicated to thoroughly evaluating and rating the performance of Wave Life Sciences Ltd (WVE) in the stock market.The consensus estimate for the next quarter is -$0.26, with high estimates of -$0.09 and low estimates of -$0.44.
Analysts are recommending an EPS of between -$0.92 and -$1.42 for the fiscal current year, implying an average EPS of -$1.16. EPS for the following year is -$1.22, with 11.0 analysts recommending between -$0.85 and -$1.77.
Revenue Estimates
A total of 14 analysts have provided revenue estimates for WVE’s current fiscal year. The highest revenue estimate was $85M, while the lowest revenue estimate was $17.87M, resulting in an average revenue estimate of $46.77M. In the same quarter a year ago, actual revenue was $108.3M
